Carisma Therapeutics to Present New Data on Anti-GPC3 In Vivo CAR-M Therapy for Hepatocellular Carcinoma at SITC 2024
Carisma Therapeutics (Nasdaq: CARM) announced new pre-clinical data presentation on their anti-GPC3 in vivo CAR-M therapy for hepatocellular carcinoma (HCC) at SITC 2024. The therapy, developed with Moderna, uses lipid nanoparticles to deliver mRNA that reprograms endogenous myeloid cells, creating an off-the-shelf treatment approach for GPC3+ solid tumors.
The data, demonstrating robust anti-tumor activity, will be presented on November 8, 2024, at the SITC Annual Meeting in Houston, Texas. The presentation focuses on targeting Glypican-3, a tumor-associated antigen commonly expressed in HCC. Two posters will be presented, including one on the pre-clinical efficacy of anti-GPC3 CAR-M and another on a Phase 1 study of anti-HER2 CAR therapy.
Carisma Therapeutics (Nasdaq: CARM) ha annunciato la presentazione di nuovi dati pre-clinici sulla loro terapia anti-GPC3 CAR-M in vivo per il carcinoma epatocellulare (HCC) al SITC 2024. La terapia, sviluppata con Moderna, utilizza nanoparticelle lipidiche per somministrare mRNA che riprogramma le cellule mieloidi endogene, creando un approccio terapeutico pronto all’uso per i tumori solidi GPC3+.
I dati, che dimostrano una robusta attività anti-tumorale, saranno presentati l'8 novembre 2024, durante l'Annual Meeting del SITC a Houston, Texas. La presentazione si concentra sul targeting della Glicoprotina-3, un antigene associato al tumore comunemente espresso nell'HCC. Saranno presentati due manifesti, uno sulla efficacia pre-clinica dell'anti-GPC3 CAR-M e l'altro su uno studio di Fase 1 della terapia anti-HER2 CAR.
Carisma Therapeutics (Nasdaq: CARM) anunció la presentación de nuevos datos preclínicos sobre su terapia anti-GPC3 CAR-M in vivo para el carcinoma hepatocelular (HCC) en el SITC 2024. La terapia, desarrollada con Moderna, utiliza nanopartículas lipídicas para entregar ARNm que reprograma las células mieloides endógenas, creando un enfoque de tratamiento disponible para tumores sólidos GPC3+.
Los datos, que demuestran una robusta actividad antitumoral, se presentarán el 8 de noviembre de 2024, en la reunión anual del SITC en Houston, Texas. La presentación se centra en el objetivo de la Glicoproteína-3, un antígeno asociado al tumor que se expresa comúnmente en el HCC. Se presentarán dos carteles, uno sobre la eficacia preclínica del anti-GPC3 CAR-M y otro sobre un estudio de Fase 1 de la terapia anti-HER2 CAR.
Carisma Therapeutics (Nasdaq: CARM)은 SITC 2024에서 간세포암(HCC)을 위한 anti-GPC3 in vivo CAR-M 치료법에 대한 새로운 전임상 데이터 발표를 발표했습니다. Moderna와 협력하여 개발된 이 치료법은 지질 나노입자를 사용하여 mRNA를 전달하고 내인성 골수 세포를 리프로그래밍하여 GPC3+ 고형 종양에 대한 즉시 사용 가능한 치료 접근 방식을 생성합니다.
강력한 항종양 활성을 입증하는 이 데이터는 2024년 11월 8일 텍사스 휴스턴에서 열리는 SITC 연례 회의에서 발표될 예정입니다. 발표는 HCC에서 일반적으로 발현되는 종양 관련 항원인 Glypican-3 표적에 중점을 둡니다. 두 개의 포스터가 발표될 예정이며, 하나는 anti-GPC3 CAR-M의 전임상 효능에 대한 것이고 다른 하나는 anti-HER2 CAR 치료의 1상 연구에 대한 것입니다.
Carisma Therapeutics (Nasdaq: CARM) a annoncé la présentation de nouvelles données précliniques sur sa thérapie anti-GPC3 CAR-M in vivo pour le carcinome hépatocellulaire (HCC) lors du SITC 2024. La thérapie, développée avec Moderna, utilise des nanoparticules lipidiques pour délivrer de l'ARNm qui reprogramme les cellules myéloïdes endogènes, créant une approche thérapeutique prête à l'emploi pour les tumeurs solides GPC3+.
Les données, démontrant une activité antitumorale robuste, seront présentées le 8 novembre 2024 lors de la réunion annuelle du SITC à Houston, au Texas. La présentation se concentre sur le ciblage de la Glypican-3, un antigène associé à la tumeur exprimé couramment dans le HCC. Deux affiches seront présentées, l'une sur l'efficacité préclinique de l'anti-GPC3 CAR-M et l'autre sur une étude de Phase 1 de la thérapie anti-HER2 CAR.
Carisma Therapeutics (Nasdaq: CARM) hat die Präsentation neuer präklinischer Daten zu ihrer anti-GPC3 in vivo CAR-M-Therapie für Hepatozelluläres Karzinom (HCC) auf dem SITC 2024 angekündigt. Die Therapie, die zusammen mit Moderna entwickelt wurde, verwendet Lipid-Nanopartikel zur Lieferung von mRNA, die endogene myeloide Zellen umprogrammiert und ein sofort einsatzbereites Therapieansatz für GPC3+ solide Tumoren schafft.
Die Daten, die eine robuste antitumorale Aktivität zeigen, werden am 8. November 2024 auf dem jährlichen SITC-Treffen in Houston, Texas, vorgestellt. Die Präsentation konzentriert sich auf das Ziel Glypikan-3, ein tumorassoziiertes Antigen, das häufig im HCC exprimiert wird. Es werden zwei Poster präsentiert, eines zur präklinischen Wirksamkeit von anti-GPC3 CAR-M und ein weiteres zu einer Phase-1-Studie der anti-HER2 CAR-Therapie.
- None.
- None.
Pre-clinical data demonstrate robust anti-tumor activity and a novel off-the-shelf approach for GPC3+ solid tumors
The abstract, titled "Pre-Clinical Efficacy of a Novel Anti-GPC3 In Vivo CAR-M for Hepatocellular Carcinoma," presents the first pre-clinical data on the development candidate targeting Glypican-3 ("GPC3"), a tumor-associated antigen commonly expressed in HCC. This novel off-the-shelf approach reprograms endogenous myeloid cells in vivo using lipid nanoparticles ("LNP") to deliver mRNA encoding CARs. The data show that this in vivo CAR-M therapy has significant potential as a treatment for GPC3+ solid tumors, including HCC.
"Our data at SITC this year highlights the groundbreaking potential of the in vivo CAR-M platform," said Steven Kelly, President and Chief Executive Officer of Carisma. "The pre-clinical results demonstrate robust anti-tumor activity and pave the way for an off-the-shelf therapy for hard-to-treat cancers like hepatocellular carcinoma. This data underscores the progress we've made, and we're eager to advance this promising therapy into clinical development."
SITC Presentations Details:
Title: Pre-clinical efficacy of a novel anti-GPC3 in vivo CAR-M for hepatocellular carcinoma
Publication Number: 329
Session Date & Time: Friday, Nov. 8, 2024
Location: Exhibit Halls A B George R. Brown Convention Center
Title: A Phase 1, First-in-Human study of autologous monocytes engineered to express an anti-HER2 chimeric antigen receptor (CAR) in participants with HER2 overexpressing solid tumors
Publication Number: 659
Session Date & Time: Friday, Nov. 8, 2024
Location: Exhibit Halls A B George R. Brown Convention Center
The poster presented at SITC 2024 will be available online in the "Publications" section of Carisma's website at https://carismatx.com/technology/publications/ following the start of the poster session.
About Carisma Therapeutics
Carisma Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on utilizing our proprietary macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. We have created a comprehensive, differentiated proprietary cell therapy platform focused on engineered macrophages and monocytes, cells that play a crucial role in both the innate and adaptive immune response. Carisma is headquartered in
Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, anticipated discovery, preclinical and clinical development activities for Carisma's product candidates, the potential safety, efficacy, benefits and addressable market for Carisma's product candidates, and clinical trial results for Carisma's product candidates. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. The words "believes," "anticipates," "estimates," "plans," "expects," "intends," "may," "could," "should," "potential," "likely," "projects," "continue," "will," "schedule," and "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements are predictions based on the Company's current expectations and projections about future events and various assumptions. Although Carisma believes that the expectations reflected in such forward-looking statements are reasonable, Carisma cannot guarantee future events, results, actions, levels of activity, performance or achievements, and the timing and results of biotechnology development and potential regulatory approval is inherently uncertain. Forward-looking statements are subject to risks and uncertainties that may cause Carisma's actual activities or results to differ significantly from those expressed in any forward-looking statement, including risks and uncertainties related to Carisma's ability to advance its product candidates, the receipt and timing of potential regulatory designations, approvals and commercialization of product candidates, clinical trial sites and our ability to enroll eligible patients, supply chain and manufacturing facilities, Carisma's ability to maintain and recognize the benefits of certain designations received by product candidates, the timing and results of preclinical and clinical trials, Carisma's ability to fund development activities and achieve development goals, Carisma's ability to protect intellectual property, and other risks and uncertainties described under the heading "Risk Factors" in Carisma's Annual Report on Form 10-K for the year ended December 31, 2023, its Quarterly Reports on Form 10-Q and other documents that Carisma files from time to time with the Securities and Exchange Commission. These forward-looking statements speak only as of the date of this press release, and Carisma undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date hereof, except as may be required by law.
Investors:
Shveta Dighe
Head of Investor Relations
investors@carismatx.com
Media Contact:
Julia Stern
(763) 350-5223
jstern@realchemistry.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/carisma-therapeutics-to-present-new-data-on-anti-gpc3-in-vivo-car-m-therapy-for-hepatocellular-carcinoma-at-sitc-2024-302295745.html
SOURCE Carisma Therapeutics Inc.
FAQ
What is the new therapy Carisma Therapeutics (CARM) is presenting at SITC 2024?
When and where will Carisma Therapeutics (CARM) present their SITC 2024 data?
What are the key findings of Carisma Therapeutics' (CARM) pre-clinical data?
Which company is collaborating with Carisma Therapeutics (CARM) on this therapy?
